KR20210098429A - 신경퇴행성 질환의 치료에서 신경보호제로서 도네코프리드 - Google Patents

신경퇴행성 질환의 치료에서 신경보호제로서 도네코프리드 Download PDF

Info

Publication number
KR20210098429A
KR20210098429A KR1020217009149A KR20217009149A KR20210098429A KR 20210098429 A KR20210098429 A KR 20210098429A KR 1020217009149 A KR1020217009149 A KR 1020217009149A KR 20217009149 A KR20217009149 A KR 20217009149A KR 20210098429 A KR20210098429 A KR 20210098429A
Authority
KR
South Korea
Prior art keywords
compound
mice
donecoprid
formula
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217009149A
Other languages
English (en)
Korean (ko)
Inventor
패트릭 달마뉴
크리스토프 호셰
실비 클라이젠
Original Assignee
우니베르씨때 드 카옌 노르망디
상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄 (씨엔알에스)
유니베르시테 드 몽펠리에
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우니베르씨때 드 카옌 노르망디, 상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄 (씨엔알에스), 유니베르시테 드 몽펠리에, 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) filed Critical 우니베르씨때 드 카옌 노르망디
Publication of KR20210098429A publication Critical patent/KR20210098429A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217009149A 2018-09-28 2019-09-27 신경퇴행성 질환의 치료에서 신경보호제로서 도네코프리드 Ceased KR20210098429A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306280.1 2018-09-28
EP18306280.1A EP3628660A1 (en) 2018-09-28 2018-09-28 Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases
PCT/EP2019/076229 WO2020065028A1 (en) 2018-09-28 2019-09-27 Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
KR20210098429A true KR20210098429A (ko) 2021-08-10

Family

ID=63798921

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009149A Ceased KR20210098429A (ko) 2018-09-28 2019-09-27 신경퇴행성 질환의 치료에서 신경보호제로서 도네코프리드

Country Status (10)

Country Link
US (1) US20220031680A1 (https=)
EP (2) EP3628660A1 (https=)
JP (1) JP2022511366A (https=)
KR (1) KR20210098429A (https=)
CN (1) CN113195452A (https=)
AU (1) AU2019346024B2 (https=)
BR (1) BR112021005952A2 (https=)
CA (1) CA3115342A1 (https=)
SG (1) SG11202103070VA (https=)
WO (1) WO2020065028A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3166060A1 (fr) 2024-09-12 2026-03-13 Université De Caen Normandie Composition pharmaceutique formulée pour être administrée par voie intranasale et utilisable pour le traitement d’une maladie neurodégénérative
FR3166146A1 (fr) 2024-09-12 2026-03-13 Université De Caen Normandie Sel de fumarate de 1-(4-amino-5-chloro-2-méthoxyphényl)-3-[1-(cycloheptylméthyl)-4-pipéridinyl]propan-1-one –Composition pharmaceutique et utilisation associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
FR2904113A1 (fr) 2006-07-21 2008-01-25 Exonhit Therapeutics S A Sa Procedes et outils pour la therapie de pathologies neurodegeneratives
CN102355902A (zh) * 2009-01-24 2012-02-15 植物药物公共有限公司 神经营养因子介导的病症的处理
FR3006686A1 (fr) * 2013-06-05 2014-12-12 Univ Caen Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant
KR101824154B1 (ko) * 2013-12-16 2018-03-14 수벤 라이프 사이언시스 리미티드 5-ｈｔ４ 수용체 작용제로서 인다졸 화합물

Also Published As

Publication number Publication date
WO2020065028A1 (en) 2020-04-02
AU2019346024B2 (en) 2024-07-18
JP2022511366A (ja) 2022-01-31
EP3628660A1 (en) 2020-04-01
AU2019346024A1 (en) 2021-04-29
SG11202103070VA (en) 2021-04-29
CA3115342A1 (en) 2020-04-02
BR112021005952A2 (pt) 2021-06-29
US20220031680A1 (en) 2022-02-03
CN113195452A (zh) 2021-07-30
EP3856716A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
Pierzynowska et al. Autophagy-dependent mechanism of genistein-mediated elimination of behavioral and biochemical defects in the rat model of sporadic Alzheimer's disease
US20230218617A1 (en) Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
Urano et al. Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β‐induced neurite atrophy
Nabi et al. Mechanisms of mitochondrial malfunction in Alzheimer’s disease: new therapeutic hope
Bailey et al. A novel effect of rivastigmine on pre‐synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s disease
JP2008520589A (ja) シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法
Yu et al. Baicalin attenuates amyloid β oligomers induced memory deficits and mitochondria fragmentation through regulation of PDE-PKA-Drp1 signalling
US20210154156A1 (en) Application of compound in inhibiting ab accumulation and treating alzheimer's disease
US12540310B2 (en) Differentiation method of neural stem cells manufactured by direct cell conversion into astrocytes
JP5968878B2 (ja) イソアクテオシドまたはその製薬上許容される塩の使用
KR20210098429A (ko) 신경퇴행성 질환의 치료에서 신경보호제로서 도네코프리드
US20210038589A1 (en) Uses, compositions and methods
KR20200116054A (ko) 봉독 추출물을 유효성분으로 함유하는 신경염증 질환 예방 또는 치료용 조성물
KR20210098428A (ko) 신경퇴행성 질환의 치료에서 신경보호제로서 아세틸콜린에스테라제 억제제 및 5-ht4 수용체 작용제의 조합물
RU2800802C2 (ru) Донекоприд как нейропротекторный агент при лечении нейродегенеративных заболеваний
JP2022519103A (ja) パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
Jiao et al. Anisomycin alleviates cognitive impairments and pathological features in 3xTg-AD mice
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
Ning et al. A novel GSK3β inhibitor ameliorates tau aggregation and neuroinflammation in Alzheimer's disease
Liu et al. Blockage of IL-17 ameliorates Aβ-induced neurotoxicity and cognitive decline
Wang et al. Neuroprotective Effect of Hydroxysafflor Yellow A on an Alzheimer’s Disease (AD)-Like Mouse Model
EP3714892B1 (en) Isolated mitochondria for use in the treatment and/or prevention of alzheimer s disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210326

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220713

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240923

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241202

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D